Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04479787 · ClinicalTrials.gov registry record · NA

Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)

A NA study, sponsored by Abbott Medical Devices.

Completed
Registry status
NA
Development phase
270
Enrollment target

NCT04479787: Completed NA study, sponsored by Abbott Medical Devices.

NCT04479787 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 270 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04479787, a NA study, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
NA
Development phase
270 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the efficacy of BurstDR dorsal column stimulation, compared with conventional medical management, in improving pain and back-related physical function in subjects suffering with chronic, refractory axial low back pain with a neuropathic component, who have not had lumbar spine surgery and for whom surgery is not an option.

Primary Outcome

Improvement in pain, defined as percentage of patients who report a ≥ 50% decrease on Numeric Rating Scale (NRS).

Interventions

  • DEVICE Spinal Cord Stimulation
  • OTHER Conventional Medical Management

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2020-07-31
Est. Completion 2024-02-26
Phase NA
Abbott Medical Devices

261 total trials

What the finished NCT04479787 record still lists

NCT04479787 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 2 interventions - of which Spinal Cord Stimulation is the first listed.

NCT04479787 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04479787 about?

NCT04479787 is a clinical study titled "Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)". The objective of this study is to evaluate the efficacy of BurstDR dorsal column stimulation, compared with conventional medical management, in improving pain and back-related physical function in subjects suffering with chronic, refractory axial low back pain with a neuropathic component, who have ...

What is the current status of trial NCT04479787?

This trial is currently completed. It is a NA study. The enrollment target is 270 participants. The study started on 2020-07-31. Estimated completion is 2024-02-26.

What interventions are being tested in trial NCT04479787?

The interventions under investigation include: Spinal Cord Stimulation (DEVICE), Conventional Medical Management (OTHER).

Who is sponsoring clinical trial NCT04479787?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04479787's enrollment target sits among peer trials

270 387th of 2000 higher than 1,609 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04479787, the US trial registry maintained by the National Library of Medicine. NCT04479787 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.